Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune
response associated with immunological memory, provided they display sufficient …

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think
about cancer treatment. Even so, for most types of cancer, only a minority of patients …

The three-way interaction between oncolytic viruses, the tumor microenvironment, and the
immune system is critical to the outcome of antitumor therapy. Classically, the immune …

Immune checkpoint inhibitors, including those targeting programmed cell death protein 1
(PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor …

Previously, we reported that killing tumor cells in vivo with the HSV thymidine
kinase/ganciclovir system generates potent antitumor immunity, determined in part by the …

Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune
response, represent a promising approach to the treatment of cancer. However, how they …

Oncolytic viruses (OV) are promising treatments for cancer, with several currently
undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested …

Purpose: Early clinical trials are under way exploring the direct oncolytic potential of
reovirus. This study addresses whether tumor infection by reovirus is also able to generate …

Purpose: Reovirus is a naturally occurring oncolytic virus in clinical trials. Although tumor
infection by reovirus can generate adaptive antitumor immunity, its therapeutic importance …

Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I–III
clinical trials. Until recently, most studies have focused on the direct antitumor properties of …